Physician profile
Vincent Hsu
NPI 1255331146
$221,798.20
in general payments reported to CMS, 2019-2025
15 companies · $62K in 2025
The $62K reported for 2025 was more than what 98% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $28K · 2021: $20K · 2022: $22K · 2023: $30K · 2024: $35K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $89K · Travel and Lodging: $18K · Consulting Fee: $16K · Food and Beverage: $2,651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $89,471.00 |
| Travel and Lodging | $18,337.40 |
| Consulting Fee | $16,490.00 |
| Food and Beverage | $2,651.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $136,058.55 | 2019-2025 | Capvaxive, Vaxneuvance |
| Sanofi Pasteur INC. | $46,428.63 | 2019-2023 | |
| Pfizer INC. | $17,691.70 | 2022-2025 | |
| Valneva USA, INC. | $13,654.88 | 2021-2024 | |
| Gilead Sciences, INC. | $7,112.30 | 2019-2024 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $209.22 | 2020 | |
| Allergan, INC. | $125.00 | 2019 | |
| Viiv Healthcare Company | $124.98 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.54 | 2019 | |
| Insmed, INC. | $119.05 | 2020 | |
| Accelerate Diagnostics INC. | $49.20 | 2019 | |
| Janssen Scientific Affairs, LLC | $31.09 | 2021 | |
| Shionogi INC | $26.25 | 2025 | Fetroja |
| Glaxosmithkline, LLC. | $23.17 | 2025 | Blujepa |
| Beckman Coulter, INC. | $22.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Hsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.